At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 109 enrolled
Drug / intervention
Galcanezumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Cluster Headache
In Brief
A Phase 3 clinical trial evaluating Galcanezumab and Placebo for Episodic Cluster Headache. Completed, enrolled 109 participants across 47 sites in 12 countries.
Detailed Summary
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as Galcanezumab in participants with episodic cluster headaches.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpisodic Cluster Headache
CountriesBelgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2015
Enrollment StartMay 2015
Primary CompletionFeb 2018
Study CompletionJun 2018
TodayJul 2026
First PostedMar 25, 2015
Enrollment StartMay 22, 2015
Primary CompletionFeb 12, 2018
Study CompletionJun 4, 2018
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 11.3 years ago
Interventions
Galcanezumabdrug
Administered SC
Placebodrug
Administered SC